Comerica Bank Has $1.51 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Comerica Bank reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,411 shares of the company’s stock after selling 943 shares during the quarter. Comerica Bank’s holdings in Moderna were worth $1,514,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of MRNA. abrdn plc raised its position in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after buying an additional 69,360 shares during the last quarter. Spire Wealth Management lifted its position in shares of Moderna by 2,150.4% in the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock worth $966,000 after acquiring an additional 22,192 shares during the period. Proficio Capital Partners LLC grew its holdings in shares of Moderna by 4,418.9% during the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company’s stock worth $6,127,000 after purchasing an additional 144,099 shares in the last quarter. South Dakota Investment Council increased its position in shares of Moderna by 4.0% during the fourth quarter. South Dakota Investment Council now owns 299,399 shares of the company’s stock valued at $12,449,000 after purchasing an additional 11,500 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock valued at $300,219,000 after purchasing an additional 171,774 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Trading Down 0.5 %

Moderna stock opened at $24.25 on Friday. The company has a market cap of $9.38 billion, a PE ratio of -2.61 and a beta of 1.99. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The company’s 50-day moving average is $28.89 and its two-hundred day moving average is $36.46.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million for the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business’s revenue for the quarter was down 35.3% on a year-over-year basis. During the same period last year, the firm earned ($3.07) earnings per share. Research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

MRNA has been the topic of several analyst reports. Barclays lowered their price target on shares of Moderna from $45.00 to $40.00 and set an “equal weight” rating on the stock in a report on Friday, May 2nd. Bank of America dropped their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. UBS Group decreased their price objective on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Morgan Stanley dropped their target price on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. Finally, Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $53.95.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.